<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-dose chemotherapy with autologous bone marrow or peripheral blood stem cell transplantation has gained widespread acceptance for the treatment of certain <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Since the introduction of this therapy in 1988 we have treated 272 patients </plain></SENT>
<SENT sid="2" pm="."><plain>Indications for high-dose chemotherapy were high-risk large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and lymphoblastic or Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in first remission (73 patients), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in chemosensitive relapse (65 patients), Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in relapse (52 patients), <z:e sem="disease" ids="C0205851" disease_type="Neoplastic Process" abbrv="">germ cell tumours</z:e> with inadequate response to chemotherapy (34 patients), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (29 patients), and other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (19 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment mortality was 1.8% </plain></SENT>
<SENT sid="4" pm="."><plain>The 3-year event-free survival and overall survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients were 48 and 61% respectively </plain></SENT>
<SENT sid="5" pm="."><plain>High-dose chemotherapy with autologous stem cell transplantation has become a safe procedure and is considered the treatment of choice for relapsed large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, relapsed <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, stage II or III <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and <z:e sem="disease" ids="C0205851" disease_type="Neoplastic Process" abbrv="">germ cell tumours</z:e> with inadequate response to <z:chebi fb="2" ids="27899">cisplatin</z:chebi>-based chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>In other situations, including aggressive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with risk factors, <z:hpo ids='HP_0011009'>acute</z:hpo> leucaemia or <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, the superiority of high-dose over conventional chemotherapy remains to be proven </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with such diseases should not receive high-dose chemotherapy outside a controlled clinical study </plain></SENT>
</text></document>